Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Retained Earnings (2018 - 2025)

Historic Retained Earnings for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to -$383.3 million.

  • TransMedics' Retained Earnings rose 1931.5% to -$383.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$383.3 million, marking a year-over-year increase of 1931.5%. This contributed to the annual value of -$468.2 million for FY2024, which is 704.06% up from last year.
  • TransMedics' Retained Earnings amounted to -$383.3 million in Q3 2025, which was up 1931.5% from -$407.7 million recorded in Q2 2025.
  • Over the past 5 years, TransMedics' Retained Earnings peaked at -$383.3 million during Q3 2025, and registered a low of -$507.7 million during Q3 2023.
  • Moreover, its 5-year median value for Retained Earnings was -$468.2 million (2024), whereas its average is -$457.2 million.
  • In the last 5 years, TransMedics' Retained Earnings crashed by 1153.77% in 2022 and then soared by 1931.5% in 2025.
  • Over the past 5 years, TransMedics' Retained Earnings (Quarter) stood at -$442.4 million in 2021, then fell by 8.19% to -$478.7 million in 2022, then dropped by 5.23% to -$503.7 million in 2023, then rose by 7.04% to -$468.2 million in 2024, then grew by 18.13% to -$383.3 million in 2025.
  • Its Retained Earnings stands at -$383.3 million for Q3 2025, versus -$407.7 million for Q2 2025 and -$442.6 million for Q1 2025.